Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all blog posts
6.20.2018

Aspirin Just as Effective as Xarelto for Preventing Clots after Hip, Knee Surgery Study Shows

By Brian Lynch
In The News, You Should Know

One way pharmaceutical companies justify expensive and potentially dangerous drugs is that they fulfill a need that no other product on the market is capable of. This argument just got weaker in the case of the blood thinner Xarelto, as a new study shows that aspirin, one of the most common and readily-available pain relievers, is just as effective as Xarelto for preventing clots after certain surgical procedures.

Funded by the Canadian Institutes of Health Research and published in the New England Journal of Medicine, the study examined 3,423 patients, of which 1,804 underwent total hip arthroplasty and 1,620 who had undergone total knee arthroplasty. All of the patients received 10 mg of oral rivaroxaban (Xarelto) until the fifth postoperative day. Then patients were randomly assigned to either continue taking Xarelto or were switched to 81 mg of aspirin per day.

The study found that venous thromboembolism (blood clots) occurred in 11 of the 1,707 aspirin patients and 12 of the 1,717 Xarelto patients. Ultimately, the study concluded that the rates of venous thromboembolism in either group were not significantly different in preventing blood clots.

“The major message here is aspirin is an effective and safe alternative to rivaroxaban” beginning five days after surgery, lead author Dr. David Anderson, told Reuters Health in a telephone interview. “And it offers a choice and potential benefits of savings to patients and the healthcare system.”

This study is the first of its kind to compare aspirin and Xarelto for replacement surgery.

Share

No Comments

Leave a Reply Cancel reply

Receive News Updates

Get the latest from Wexler Wallace LLP & stay informed.

Categories

  • Media Appearances
  • Uncategorized
  • Columns
    • Guest Post
    • Ken Wexler
    • Ed Wallace
  • Practice Areas
    • Consumer Protection
    • Mass Tort Litigation
    • Business & Commercial Litigation
    • Healthcare Litigation
    • Employment Litigation
  • Cases
  • Hall Of Shame
    • Villain Of The Week
  • In The News
    • Public Victories
  • Featured Investigations
  • The Firm
    • News releases
    • Around The World
    • Our Professionals
    • Chicago
  • You Should Know
    • For Investors
    • For Businesses
    • For Consumers
  • Featured Cases
  • awards
  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP